<DOC>
	<DOCNO>NCT02342418</DOCNO>
	<brief_summary>This open label , single-dose , pharmacokinetic study 9 obese 9 age- , sex- , ideal body weight- match non-obese subject . Qualifying subject complete informed consent receive single intravenous dose tedizolid collection 11 blood sample 72 hour post dose .</brief_summary>
	<brief_title>Single Dose PK IV Tedizolid Phosphate Morbidly Obese Non-Obese Adults</brief_title>
	<detailed_description>Subjects present clinical research unit morning ( approximately 6:30 a.m. ) dose day . A urine pregnancy test perform rule pregnancy prior administration tedizolid phosphate dose female subject . The subject 's height , total body weight , vital sign ( heart rate , blood pressure , temperature , respiratory rate ) record . Subjects judge ( study physician ) healthy enough participate proceed study procedure . An 18-20 gauge intravenous peripheral catheter insert antecubital vein vein fore-arm non-dominant arm sequential blood sampling , initial predose blood sample ( 5 mL ) collect . A minimum 3-5 mL blood require per pharmacokinetic sample time-point . Each blood collection tube pre-labeled : 1 . ) study protocol number ; 2 . ) subject study number ; 3 . ) date collection ; 4 . ) time-point . A 0.9 % Sodium Chloride infusion may run peripheral line 30 40 mL per hour maintain catheter patency 12 hour sample phase . Alternatively , heparin lock technique utilized maintain intravascular catheter patency . A single-dose tedizolid phosphate administer intravenous infusion ( 250 mL normal saline ) 1 hour ( ~8:00 a.m. ) . The intravenous administration tube flush 0.9 % Sodium Chloride infusion 250 mL per hour ( match tedizolid phosphate rate infusion ) 10 minute ensure complete dose delivery . Blood sample ( 5 mL ) collect 0.5 ( middle infusion ) , 1 ( end infusion ) , 2 , 4 , 6 , 8 , 12 , 24 , 48 , 72 hour post dose blood collection tube . The plasma harvest ( centrifugation 4°C ) within 60 minute collection store -70°C two aliquot analysis . The intravascular catheter `` dead-space '' volume discard prior blood sample collection withdraw 1.5-2 mL catheter ensure unintentional sample dilution . The intravascular catheter remove 12 hour sample subject discharge research unit . The subject return research unit blood sample collection daily basis follow point : 24 ( Visit 3 ) , 48 ( Visit 4 ) , 72 hour ( Visit 5 ) dose via peripheral vein needle stick . The exact date time blood sample collection record case report form . Each blood sample tube invert make up-right 5 time afford mix blood anticoagulant . Blood sample maintain wet ice centrifuge 1200 g 10 minute 4°C within 60 minute collection yield approximately 2 mL plasma per 5 mL blood collection . The plasma sample transfer -20°C freezer storage -70°C end sample collection period analysis .</detailed_description>
	<mesh_term>Torezolid phosphate</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Nonsmoking lightsmoking ( ≤ 5 cigarette per day ) volunteer Estimated CLcr ( CockcroftGault equation ) ≥ 90 mL/min Female subject childbearing potential ( CBP ) either surgically sterilize , use hormonal contraceptive effective barrier method contraception ( diaphragm , cervical cap , condom ) agree abstain sex time prestudy screening , entire study period 4 week follow study period Platelets count ≥ 140,000/mL Absolute neutrophil count ( ANC ) ≥ 1800/mL History hypersensitivity reaction oxazolidinone BMI &lt; 18.5 kg/m2 Any chronic medical condition require pharmacologic therapy Transaminases ( AST ALT ) &gt; 2.5 x upper limit normal Total bilirubin &gt; 1.5 x upper limit normal Positive urine pregnancy test ( female ) Abnormal electrocardiogram ( ECG ) judge study physician Unable tolerate venipuncture multiple blood draw Clinically significant abnormal physical examination define physical finding require clinical workup Unable independently provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>